Epistem Ltd
| Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses. The Contract Research Division delivers innovative preclinical research services in the areas of oncology, mucositis, inflammation. |
Dr Julie Foster
Business Development Manager, Contract Research Services, Europe
Fusion Antibodies
| Fusion Antibodies is a CRO that offers a range of royalty free, fee-for-services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates. |
Dr Paul Kerr
Managing Director
Ockham Oncology
| Ockham provides high-quality, global clinical research and strategic development services to pharmaceutical and biotechnology companies, assisting them in the achievement of their strategic planning, technology transfer, licensing, and regulatory planning. |
Ms Juliette Almond
Ms Andrea Cotton-Berry
Patheon (UK) Ltd 
| Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides services to approximately 300 customers throughout the world. |
Dr Simon Bryant
Business Development Manager
Mr Alan Lahaise
Senior Director, Business Development
Physiomics plc
Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials. This optimisation improves the efficacy of combinations in pre-clinical xenografts.
The company is also developing:
- Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials.
- Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates early on in the drug discovery process.
- Drug combinations database, for researchers and clinicians to rapidly access literature data on pre-clinical and clinical regimens and their effects.
Physiomics has worked with Eli Lilly since 2007 and recently added a further large pharmaceutical client. In addition, Physiomics has collaborated with a number of other companies including Bayer Technology Services, Sareum, ValiRx, Cancer Research Technologies and Cyclacel. Fee-for-service, licensing and revenue sharing options are available.
Dr Mark Chadwick
Reach Separations
| REACH SEPARATIONS is a dedicated Chromatography Purification solution. We have exceptional capabilities in Separation Science, offering custom solutions for companies in the Pharmaceutical Discovery and Fine Chemical environments. |
